tradingkey.logo

CORRECTED-Coherus Oncology Q4 revenue misses estimates

ReutersMar 9, 2026 9:38 PM


Overview

  • Oncology firm's Q4 revenue missed analyst expectations

  • LOQTORZI product sales more than doubled yr/yr, driven by higher patient demand

  • Company reduced debt by 90% from $480 mln to $38.8 mln over 2024-2025


Outlook

  • Coherus anticipates initial data readouts for tagmokitug studies in mid-2026

  • Company plans to begin mCRPC study with pasritamig in 2H 2026

  • Coherus expects first data from casdozokitug Phase 2 trial in mid-2026


Result Drivers

  • LOQTORZI SALES GROWTH - LOQTORZI net revenue more than doubled to $40.8 mln in 2025 from $19.1 mln in 2024, driven by higher patient demand and longer treatment durations

Company press release: ID:nGNXc55pb6


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Miss

$12.75 mln

$13.94 mln (6 Analysts)

Q4 EPS From Contops

-$0.39

Q4 Adjusted Net Income From Contops

Miss

-$40.42 mln

-$35.15 mln (5 Analysts)

Q4 Net Income

-$37.64 mln

Q4 Operating Income

-$45.88 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Coherus Oncology Inc is $6.00, about 229.7% above its March 6 closing price of $1.82


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI